CXCL12/CXCR4 signaling governs ischemic neurovascular pathophysiology and repair: a multidimensional contextual analysis.

Authors

Shahram Eisa-Beygi, Hao Wu, Kui Cui, Kulandaisamy Arulsamy, Bo Zhu, Beibei Wang, Bandana Singh, Krishan Gupta, Jianing Gao, Scott Wong, Joyce Bischoff, Hanqiang Deng, Hong Chen

Published in

Angiogenesis. Volume 29. Issue 4. Aug 20, 2026. Epub Aug 20, 2026.

Abstract

Ischemic stroke is a global health crisis necessitating targeted therapeutic strategies. Central to post-stroke pathology and repair is the CXCL12 signaling axis. In this review, we discuss the context-dependent roles of CXCL12 and its canonical receptor, CXCR4, within the post-ischemic microenvironment. The CXCL12/CXCR4 axis exhibits a temporal duality across the evolution of the neurovascular lesion; however, current evidence necessitates moving beyond a strictly binary framework. While the acute phase involves pathological cascades, such as blood-brain barrier disruption and leukocyte infiltration, the axis is simultaneously essential for recruiting protective innate immune subsets. During subsequent subacute and chronic phases, it governs essential restorative processes, including neurogenesis, angiogenesis, and remyelination. This complex temporal shift is mediated by the interplay between distinct CXCL12 isoforms and the regulatory influence of the atypical receptor ACKR3/CXCR7. Furthermore, these endogenous repair mechanisms exhibit synergies with non-pharmacological interventions, notably environmental enrichment and remote ischemic postconditioning. Our multidimensional model suggests that the functional outcome of CXCL12/CXCR4 signaling is determined by the intersection of timing, cell type, receptor availability, and adaptive responses to physiological stimuli. We synthesize fundamental mechanistic data with translational insights to evaluate the therapeutic potential of this axis and the pharmacological barriers to future regenerative strategies.

PMID:
42625089
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.